Clinical trials: Human Papillomavirus Vaccines
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Genital Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in…
- Trial name
- NCT05314023
- Testing
- 9vHPV vaccine
- Where
- 5 sites in China
- Volunteers
- 1,590 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Vaccine Knowledge
Health Beliefs, Behaviors, and Healthcare Experiences Among United States Young and Mid-Age Adults
The study will provide important insight into current HPV vaccine knowledge/awareness, health beliefs, affect, vaccine discussions, decision preparedness, and vaccine intentions and behaviors among those ages 18-45, while…
- Trial name
- NCT04766164
- Testing
- Survey
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
HPV Vaccines
Increasing HPV Vaccination in Community-Based Pediatric Practices
The central goal of this study is to identify the optimal approach to implementing an evidence-based practice facilitation (PF) intervention for the uptake and completion of HPV vaccine among adolescents receiving care in the…
- Trial name
- NCT03399396
- Testing
- Practice facilitation for HPV vaccine
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Pamela Hull
Human Papilloma Virus-Related Cervical Carcinoma
An Intervention Promoting HPV Vaccination in Safety-net Clinics
This randomized controlled trial is designed to evaluate whether a behavioral intervention that includes three components: 1) reminder letters and education materials delivered before the clinic visit, 2) telephone recalls after…
- Trial name
- NCT01729429
- Testing
- HPV brochure, recall, reminders, General Adolescent Vaccine Brochure
- Where
- 2 sites in United States
- Volunteers
- 831 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Human Papillomavirus (HPV) Infection, HPV Vaccination Acceptance/Intention
Effect of Different HPV Education Methods on Vaccination Intention in Young Women
Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination.
- Trial name
- NCT07420556
- Testing
- Video-Based HPV Education, Face-to-Face HPV Education
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Emel GÜÇLÜ CİHAN
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD.…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
- Trial name
- NCT04537156
- Testing
- Nonavalent HPV vaccine, Bivalent HPV vaccine
- Where
- 2 sites in China
- Volunteers
- 9,327 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papillomavirus (HPV) Vaccines
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low.
- Trial name
- NCT03429413
- Testing
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Where
- United States
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of Florida
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02979535
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
- Where
- Mexico
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04704908
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 979 people
- Sponsor
- Jun Zhang
Cervical Cancer Screening, Vaccination Uptake
Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination
Cervical cancer (CC), primarily caused by persistent infection with high-risk human papillomavirus (HPV) types, remains a significant public health issue.
- Trial name
- NCT06995157
- Testing
- Offering HPV vaccine
- Where
- Slovenia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV 16 Infection
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.
- Trial name
- NCT00365378
- Testing
- Comparator: HPV 16 L1 Vaccine
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities
This project will compare the rate of regression of minimally abnormal Pap smears to normal in women who receive Gardasil to a historical control group.
- Trial name
- NCT00501189
- Testing
- human papillomavirus vaccine L1, type 6,11,16,18
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eisenhower Army Medical Center
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years ,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT03206255
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 940 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Healthy
Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico
In September 2009 the National Vaccination Council approved the policy for anti-HPV vaccination in 9-year-old girls with an extended scheme of 0, 6, and 60 months, under the following justification: Antibody induction due to the…
- Trial name
- NCT01717118
- Testing
- Bivalent Vaccines, Tetravalent Vaccine
- Where
- Mexico
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
HPV Vaccine Acceptability
Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability
This study aims at evaluating the effectiveness, efficiency and implementation of a multicomponent intervention (components being applied in combination or alone) on the acceptability of HPV vaccine among French adolescents…
- Trial name
- PrevHPV (NCT04945655)
- Testing
- Adolescents and parents' education and motivation at school (component 1), General practitioners' training (component 2), Access to vaccination at school (component 3)
- Where
- France
- Volunteers
- 30,739 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France